Global Cancer Immunotherapies Market Insights, Forecast to 2029

Global Cancer Immunotherapies Market Insights, Forecast to 2029

Table of Contents
1 Study Coverage
1.1 Cancer Immunotherapies Product Introduction
1.2 Market by Type
1.2.1 Global Cancer Immunotherapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies (MABs)
1.2.3 Cancer Vaccines
1.2.4 Immunomodulators
1.2.5 Adoptive Cell transfer
1.2.6 Checkpoint Inhibitors
1.3 Market by Application
1.3.1 Global Cancer Immunotherapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Breast Cancer
1.3.3 Leukemia
1.3.4 Lymphoma
1.3.5 Melanoma
1.3.6 Colorectal Cancer
1.3.7 Non-Small Cell Lung Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Cancer Immunotherapies Sales Estimates and Forecasts 2018-2029
2.2 Global Cancer Immunotherapies Revenue by Region
2.2.1 Global Cancer Immunotherapies Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Cancer Immunotherapies Revenue by Region (2018-2023)
2.2.3 Global Cancer Immunotherapies Revenue by Region (2024-2029)
2.2.4 Global Cancer Immunotherapies Revenue Market Share by Region (2018-2029)
2.3 Global Cancer Immunotherapies Sales Estimates and Forecasts 2018-2029
2.4 Global Cancer Immunotherapies Sales by Region
2.4.1 Global Cancer Immunotherapies Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Cancer Immunotherapies Sales by Region (2018-2023)
2.4.3 Global Cancer Immunotherapies Sales by Region (2024-2029)
2.4.4 Global Cancer Immunotherapies Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Cancer Immunotherapies Sales by Manufacturers
3.1.1 Global Cancer Immunotherapies Sales by Manufacturers (2018-2023)
3.1.2 Global Cancer Immunotherapies Sales Market Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Cancer Immunotherapies in 2022
3.2 Global Cancer Immunotherapies Revenue by Manufacturers
3.2.1 Global Cancer Immunotherapies Revenue by Manufacturers (2018-2023)
3.2.2 Global Cancer Immunotherapies Revenue Market Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Cancer Immunotherapies Revenue in 2022
3.3 Global Key Players of Cancer Immunotherapies, Industry Ranking, 2021 VS 2022 VS 2023
3.4 Global Cancer Immunotherapies Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Cancer Immunotherapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Cancer Immunotherapies, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Cancer Immunotherapies, Product Offered and Application
3.8 Global Key Manufacturers of Cancer Immunotherapies, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Cancer Immunotherapies Sales by Type
4.1.1 Global Cancer Immunotherapies Historical Sales by Type (2018-2023)
4.1.2 Global Cancer Immunotherapies Forecasted Sales by Type (2024-2029)
4.1.3 Global Cancer Immunotherapies Sales Market Share by Type (2018-2029)
4.2 Global Cancer Immunotherapies Revenue by Type
4.2.1 Global Cancer Immunotherapies Historical Revenue by Type (2018-2023)
4.2.2 Global Cancer Immunotherapies Forecasted Revenue by Type (2024-2029)
4.2.3 Global Cancer Immunotherapies Revenue Market Share by Type (2018-2029)
4.3 Global Cancer Immunotherapies Price by Type
4.3.1 Global Cancer Immunotherapies Price by Type (2018-2023)
4.3.2 Global Cancer Immunotherapies Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Cancer Immunotherapies Sales by Application
5.1.1 Global Cancer Immunotherapies Historical Sales by Application (2018-2023)
5.1.2 Global Cancer Immunotherapies Forecasted Sales by Application (2024-2029)
5.1.3 Global Cancer Immunotherapies Sales Market Share by Application (2018-2029)
5.2 Global Cancer Immunotherapies Revenue by Application
5.2.1 Global Cancer Immunotherapies Historical Revenue by Application (2018-2023)
5.2.2 Global Cancer Immunotherapies Forecasted Revenue by Application (2024-2029)
5.2.3 Global Cancer Immunotherapies Revenue Market Share by Application (2018-2029)
5.3 Global Cancer Immunotherapies Price by Application
5.3.1 Global Cancer Immunotherapies Price by Application (2018-2023)
5.3.2 Global Cancer Immunotherapies Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Cancer Immunotherapies Market Size by Type
6.1.1 US & Canada Cancer Immunotherapies Sales by Type (2018-2029)
6.1.2 US & Canada Cancer Immunotherapies Revenue by Type (2018-2029)
6.2 US & Canada Cancer Immunotherapies Market Size by Application
6.2.1 US & Canada Cancer Immunotherapies Sales by Application (2018-2029)
6.2.2 US & Canada Cancer Immunotherapies Revenue by Application (2018-2029)
6.3 US & Canada Cancer Immunotherapies Market Size by Country
6.3.1 US & Canada Cancer Immunotherapies Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Cancer Immunotherapies Sales by Country (2018-2029)
6.3.3 US & Canada Cancer Immunotherapies Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Cancer Immunotherapies Market Size by Type
7.1.1 Europe Cancer Immunotherapies Sales by Type (2018-2029)
7.1.2 Europe Cancer Immunotherapies Revenue by Type (2018-2029)
7.2 Europe Cancer Immunotherapies Market Size by Application
7.2.1 Europe Cancer Immunotherapies Sales by Application (2018-2029)
7.2.2 Europe Cancer Immunotherapies Revenue by Application (2018-2029)
7.3 Europe Cancer Immunotherapies Market Size by Country
7.3.1 Europe Cancer Immunotherapies Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Cancer Immunotherapies Sales by Country (2018-2029)
7.3.3 Europe Cancer Immunotherapies Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Cancer Immunotherapies Market Size
8.1.1 China Cancer Immunotherapies Sales (2018-2029)
8.1.2 China Cancer Immunotherapies Revenue (2018-2029)
8.2 China Cancer Immunotherapies Market Size by Application
8.2.1 China Cancer Immunotherapies Sales by Application (2018-2029)
8.2.2 China Cancer Immunotherapies Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Cancer Immunotherapies Market Size by Type
9.1.1 Asia Cancer Immunotherapies Sales by Type (2018-2029)
9.1.2 Asia Cancer Immunotherapies Revenue by Type (2018-2029)
9.2 Asia Cancer Immunotherapies Market Size by Application
9.2.1 Asia Cancer Immunotherapies Sales by Application (2018-2029)
9.2.2 Asia Cancer Immunotherapies Revenue by Application (2018-2029)
9.3 Asia Cancer Immunotherapies Sales by Region
9.3.1 Asia Cancer Immunotherapies Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Cancer Immunotherapies Revenue by Region (2018-2029)
9.3.3 Asia Cancer Immunotherapies Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Cancer Immunotherapies Market Size by Type
10.1.1 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Cancer Immunotherapies Market Size by Application
10.2.1 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country
10.3.1 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Company Information
11.1.2 Amgen Overview
11.1.3 Amgen Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.1.4 Amgen Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.2.4 AstraZeneca Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 AstraZeneca Recent Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Overview
11.3.3 Roche Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.3.4 Roche Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Roche Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb Overview
11.4.3 Bristol-Myers Squibb Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.4.4 Bristol-Myers Squibb Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Overview
11.5.3 Bayer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.5.4 Bayer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bayer Recent Developments
11.6 Merck
11.6.1 Merck Company Information
11.6.2 Merck Overview
11.6.3 Merck Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.6.4 Merck Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Merck Recent Developments
11.7 ARMO BioSciences (Eli Lilly)
11.7.1 ARMO BioSciences (Eli Lilly) Company Information
11.7.2 ARMO BioSciences (Eli Lilly) Overview
11.7.3 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.7.4 ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 ARMO BioSciences (Eli Lilly) Recent Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Overview
11.8.3 Novartis Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.8.4 Novartis Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Novartis Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Overview
11.9.3 Pfizer Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.9.4 Pfizer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Pfizer Recent Developments
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Information
11.10.2 Johnson & Johnson Overview
11.10.3 Johnson & Johnson Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.10.4 Johnson & Johnson Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Johnson & Johnson Recent Developments
11.11 AbbVie
11.11.1 AbbVie Company Information
11.11.2 AbbVie Overview
11.11.3 AbbVie Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.11.4 AbbVie Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 AbbVie Recent Developments
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Information
11.12.2 Gilead Sciences Overview
11.12.3 Gilead Sciences Cancer Immunotherapies Sales, Price, Revenue and Gross Margin (2018-2023)
11.12.4 Gilead Sciences Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Gilead Sciences Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Cancer Immunotherapies Industry Chain Analysis
12.2 Cancer Immunotherapies Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Cancer Immunotherapies Production Mode & Process
12.4 Cancer Immunotherapies Sales and Marketing
12.4.1 Cancer Immunotherapies Sales Channels
12.4.2 Cancer Immunotherapies Distributors
12.5 Cancer Immunotherapies Customers
13 Market Dynamics
13.1 Cancer Immunotherapies Industry Trends
13.2 Cancer Immunotherapies Market Drivers
13.3 Cancer Immunotherapies Market Challenges
13.4 Cancer Immunotherapies Market Restraints
14 Key Findings in The Global Cancer Immunotherapies Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Cancer Immunotherapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Monoclonal Antibodies (MABs)
Table 3. Major Manufacturers of Cancer Vaccines
Table 4. Major Manufacturers of Immunomodulators
Table 5. Major Manufacturers of Adoptive Cell transfer
Table 6. Major Manufacturers of Checkpoint Inhibitors
Table 7. Global Cancer Immunotherapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Cancer Immunotherapies Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 9. Global Cancer Immunotherapies Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Cancer Immunotherapies Revenue by Region (2024-2029) & (US$ Million)
Table 11. Global Cancer Immunotherapies Revenue Market Share by Region (2018-2023)
Table 12. Global Cancer Immunotherapies Revenue Market Share by Region (2024-2029)
Table 13. Global Cancer Immunotherapies Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 14. Global Cancer Immunotherapies Sales by Region (2018-2023) & (K Units)
Table 15. Global Cancer Immunotherapies Sales by Region (2024-2029) & (K Units)
Table 16. Global Cancer Immunotherapies Sales Market Share by Region (2018-2023)
Table 17. Global Cancer Immunotherapies Sales Market Share by Region (2024-2029)
Table 18. Global Cancer Immunotherapies Sales by Manufacturers (2018-2023) & (K Units)
Table 19. Global Cancer Immunotherapies Sales Share by Manufacturers (2018-2023)
Table 20. Global Cancer Immunotherapies Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Cancer Immunotherapies Revenue Share by Manufacturers (2018-2023)
Table 22. Global Key Players of Cancer Immunotherapies, Industry Ranking, 2021 VS 2022 VS 2023
Table 23. Cancer Immunotherapies Price by Manufacturers 2018-2023 (USD/Unit)
Table 24. Global Cancer Immunotherapies Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Cancer Immunotherapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Immunotherapies as of 2022)
Table 26. Global Key Manufacturers of Cancer Immunotherapies, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Cancer Immunotherapies, Product Offered and Application
Table 28. Global Key Manufacturers of Cancer Immunotherapies, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
Table 31. Global Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
Table 32. Global Cancer Immunotherapies Sales Share by Type (2018-2023)
Table 33. Global Cancer Immunotherapies Sales Share by Type (2024-2029)
Table 34. Global Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
Table 36. Global Cancer Immunotherapies Revenue Share by Type (2018-2023)
Table 37. Global Cancer Immunotherapies Revenue Share by Type (2024-2029)
Table 38. Cancer Immunotherapies Price by Type (2018-2023) & (USD/Unit)
Table 39. Global Cancer Immunotherapies Price Forecast by Type (2024-2029) & (USD/Unit)
Table 40. Global Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
Table 41. Global Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
Table 42. Global Cancer Immunotherapies Sales Share by Application (2018-2023)
Table 43. Global Cancer Immunotherapies Sales Share by Application (2024-2029)
Table 44. Global Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
Table 46. Global Cancer Immunotherapies Revenue Share by Application (2018-2023)
Table 47. Global Cancer Immunotherapies Revenue Share by Application (2024-2029)
Table 48. Cancer Immunotherapies Price by Application (2018-2023) & (USD/Unit)
Table 49. Global Cancer Immunotherapies Price Forecast by Application (2024-2029) & (USD/Unit)
Table 50. US & Canada Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
Table 51. US & Canada Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
Table 52. US & Canada Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
Table 53. US & Canada Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
Table 54. US & Canada Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
Table 55. US & Canada Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
Table 56. US & Canada Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
Table 57. US & Canada Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
Table 58. US & Canada Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 59. US & Canada Cancer Immunotherapies Revenue by Country (2018-2023) & (US$ Million)
Table 60. US & Canada Cancer Immunotherapies Revenue by Country (2024-2029) & (US$ Million)
Table 61. US & Canada Cancer Immunotherapies Sales by Country (2018-2023) & (K Units)
Table 62. US & Canada Cancer Immunotherapies Sales by Country (2024-2029) & (K Units)
Table 63. Europe Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
Table 64. Europe Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
Table 65. Europe Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
Table 66. Europe Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
Table 67. Europe Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
Table 68. Europe Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
Table 69. Europe Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
Table 70. Europe Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
Table 71. Europe Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 72. Europe Cancer Immunotherapies Revenue by Country (2018-2023) & (US$ Million)
Table 73. Europe Cancer Immunotherapies Revenue by Country (2024-2029) & (US$ Million)
Table 74. Europe Cancer Immunotherapies Sales by Country (2018-2023) & (K Units)
Table 75. Europe Cancer Immunotherapies Sales by Country (2024-2029) & (K Units)
Table 76. China Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
Table 77. China Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
Table 78. China Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
Table 79. China Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
Table 80. China Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
Table 81. China Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
Table 82. China Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
Table 83. China Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
Table 84. Asia Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
Table 85. Asia Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
Table 86. Asia Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
Table 87. Asia Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
Table 88. Asia Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
Table 89. Asia Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
Table 90. Asia Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
Table 91. Asia Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
Table 92. Asia Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 93. Asia Cancer Immunotherapies Revenue by Region (2018-2023) & (US$ Million)
Table 94. Asia Cancer Immunotherapies Revenue by Region (2024-2029) & (US$ Million)
Table 95. Asia Cancer Immunotherapies Sales by Region (2018-2023) & (K Units)
Table 96. Asia Cancer Immunotherapies Sales by Region (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Type (2018-2023) & (K Units)
Table 98. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Type (2024-2029) & (K Units)
Table 99. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Type (2018-2023) & (US$ Million)
Table 100. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Type (2024-2029) & (US$ Million)
Table 101. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Application (2018-2023) & (K Units)
Table 102. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Application (2024-2029) & (K Units)
Table 103. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Application (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Application (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Cancer Immunotherapies Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 106. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Cancer Immunotherapies Revenue by Country (2024-2029) & (US$ Million)
Table 108. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country (2018-2023) & (K Units)
Table 109. Middle East, Africa and Latin America Cancer Immunotherapies Sales by Country (2024-2029) & (K Units)
Table 110. Amgen Company Information
Table 111. Amgen Description and Major Businesses
Table 112. Amgen Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. Amgen Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Amgen Recent Developments
Table 115. AstraZeneca Company Information
Table 116. AstraZeneca Description and Major Businesses
Table 117. AstraZeneca Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. AstraZeneca Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. AstraZeneca Recent Developments
Table 120. Roche Company Information
Table 121. Roche Description and Major Businesses
Table 122. Roche Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Roche Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Roche Recent Developments
Table 125. Bristol-Myers Squibb Company Information
Table 126. Bristol-Myers Squibb Description and Major Businesses
Table 127. Bristol-Myers Squibb Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Bristol-Myers Squibb Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Bristol-Myers Squibb Recent Developments
Table 130. Bayer Company Information
Table 131. Bayer Description and Major Businesses
Table 132. Bayer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Bayer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Bayer Recent Developments
Table 135. Merck Company Information
Table 136. Merck Description and Major Businesses
Table 137. Merck Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Merck Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Merck Recent Developments
Table 140. ARMO BioSciences (Eli Lilly) Company Information
Table 141. ARMO BioSciences (Eli Lilly) Description and Major Businesses
Table 142. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. ARMO BioSciences (Eli Lilly) Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. ARMO BioSciences (Eli Lilly) Recent Developments
Table 145. Novartis Company Information
Table 146. Novartis Description and Major Businesses
Table 147. Novartis Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 148. Novartis Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Novartis Recent Developments
Table 150. Pfizer Company Information
Table 151. Pfizer Description and Major Businesses
Table 152. Pfizer Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 153. Pfizer Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Pfizer Recent Developments
Table 155. Johnson & Johnson Company Information
Table 156. Johnson & Johnson Description and Major Businesses
Table 157. Johnson & Johnson Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 158. Johnson & Johnson Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. Johnson & Johnson Recent Developments
Table 160. AbbVie Company Information
Table 161. AbbVie Description and Major Businesses
Table 162. AbbVie Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 163. AbbVie Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. AbbVie Recent Developments
Table 165. Gilead Sciences Company Information
Table 166. Gilead Sciences Description and Major Businesses
Table 167. Gilead Sciences Cancer Immunotherapies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 168. Gilead Sciences Cancer Immunotherapies Product Model Numbers, Pictures, Descriptions and Specifications
Table 169. Gilead Sciences Recent Developments
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Cancer Immunotherapies Distributors List
Table 173. Cancer Immunotherapies Customers List
Table 174. Cancer Immunotherapies Market Trends
Table 175. Cancer Immunotherapies Market Drivers
Table 176. Cancer Immunotherapies Market Challenges
Table 177. Cancer Immunotherapies Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Cancer Immunotherapies Product Picture
Figure 2. Global Cancer Immunotherapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Cancer Immunotherapies Market Share by Type in 2022 & 2029
Figure 4. Monoclonal Antibodies (MABs) Product Picture
Figure 5. Cancer Vaccines Product Picture
Figure 6. Immunomodulators Product Picture
Figure 7. Adoptive Cell transfer Product Picture
Figure 8. Checkpoint Inhibitors Product Picture
Figure 9. Global Cancer Immunotherapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 10. Global Cancer Immunotherapies Market Share by Application in 2022 & 2029
Figure 11. Breast Cancer
Figure 12. Leukemia
Figure 13. Lymphoma
Figure 14. Melanoma
Figure 15. Colorectal Cancer
Figure 16. Non-Small Cell Lung Cancer
Figure 17. Cancer Immunotherapies Report Years Considered
Figure 18. Global Cancer Immunotherapies Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 19. Global Cancer Immunotherapies Revenue 2018-2029 (US$ Million)
Figure 20. Global Cancer Immunotherapies Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 21. Global Cancer Immunotherapies Revenue Market Share by Region (2018-2029)
Figure 22. Global Cancer Immunotherapies Sales 2018-2029 ((K Units)
Figure 23. Global Cancer Immunotherapies Sales Market Share by Region (2018-2029)
Figure 24. US & Canada Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
Figure 25. US & Canada Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Europe Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
Figure 27. Europe Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
Figure 28. China Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
Figure 29. China Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
Figure 30. Asia (excluding China) Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
Figure 31. Asia (excluding China) Cancer Immunotherapies Revenue YoY (2018-2029) & (US$ Million)
Figure 32. Middle East, Africa and Latin America Cancer Immunotherapies Sales YoY (2018-2029) & (K Units)
Figure 33. Middle East, Africa and Latin Americ

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Cancer Immunomodulator Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Cancer Immunomodulator market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cancer Immunomodulator is estimated to increase from $ million in 2023 to reach $ ......

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 158

According to our LPI (LP Information) latest study, the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size was valued at US$ 14070 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is forecast to a readjusted size of US$ 57240 million by 2030 with a CAGR of 22.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells (CTCs) and Canc......

Global Circulating Tumor Cells Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 131

According to our LPI (LP Information) latest study, the global Circulating Tumor Cells market size was valued at US$ 1550.1 million in 2023. With growing demand in downstream market, the Circulating Tumor Cells is forecast to a readjusted size of US$ 5942.1 million by 2030 with a CAGR of 21.2% during review period. The research report highlights the growth potential of the global Circulating Tumor Cells market. Circulating Tumor Cells are expected to show stable growth in the future mark......

Global Circulating Tumor Cells Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 125

According to our (Global Info Research) latest study, the global Circulating Tumor Cells market size was valued at USD 1630.5 million in 2023 and is forecast to a readjusted size of USD 5681.6 million by 2030 with a CAGR of 19.5% during review period. Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of......

Small Molecule Targeted Cancer Therapy - Global Market Insights and Sales Trends 2024

Published: 27-Dec-2023        Price: US 3350 Onwards        Pages: 112

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking By Company; 3) comprehensive presentation of the global market for Small Molecule Targeted Cancer Therapy, with......

Global Cancer Gene Therapy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101

Market Overview of Global Cancer Gene Therapy market: According to our latest research, the global Cancer Gene Therapy market looks promising in the next 5 years. As of 2022, the global Cancer Gene Therapy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Gene Th......

T-Cell Immunotherapy - Global Market Insights and Sales Trends 2024

Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 85

CAR T cell therapy is a type of cancer immunotherapy treatment that uses immune cells called T cells that are genetically altered in a lab to enable them in locating in destroying cancer cells more effectively. The global T-Cell Immunotherapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of T-Cell Immunotherapy in various end use industries. The expanding demands from the Stomach ......

Global Kaposi Sarcoma Market Status and Outlook 2023-2028

Published: 22-Dec-2023        Price: US 3160 Onwards        Pages: 107

Kaposi's sarcoma is a type of cancer that forms in the lining of blood and lymph vessels. The tumors (lesions) of Kaposi's sarcoma typically appear as painless purplish spots on the legs, feet or face. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking a......

Global Cancer Immunomodulator Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 21-Dec-2023        Price: US 3380 Onwards        Pages: 118

Market Overview of Global Cancer Immunomodulator market: According to our latest research, the global Cancer Immunomodulator market looks promising in the next 5 years. As of 2022, the global Cancer Immunomodulator market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cance......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs